Join Growin Stock Community!

Genfit s.a.GNFT.US Overview

US StockHealthcare
(No presentation for GNFT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GNFT AI Insights

GNFT Overall Performance

GNFT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GNFT Recent Performance

-

Genfit s.a.

-3.61%

Avg of Sector

-2.16%

S&P500

GNFT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GNFT Key Information

GNFT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GNFT Profile

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Price of GNFT

GNFT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GNFT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.42
PB Ratio
4.89
Price-to-FCF
4.20
METRIC
VALUE
vs. INDUSTRY
Gross Margin
102.14%
Net Margin
-71.19%
Revenue Growth (YoY)
-29.36%
Profit Growth (YoY)
-27.85%
3-Year Revenue Growth
-12.44%
3-Year Profit Growth
-18.96%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.42
PB Ratio
4.89
Price-to-FCF
4.20
Gross Margin
102.14%
Net Margin
-71.19%
Revenue Growth (YoY)
-29.36%
Profit Growth (YoY)
-27.85%
3-Year Revenue Growth
-12.44%
3-Year Profit Growth
-18.96%

  • When is GNFT's latest earnings report released?

    The most recent financial report for Genfit s.a. (GNFT) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GNFT's short-term business performance and financial health. For the latest updates on GNFT's earnings releases, visit this page regularly.

  • How much debt does GNFT have?

    As of the end of the reporting period, Genfit s.a. (GNFT) had total debt of 138.91M, with a debt ratio of 0.64. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does GNFT have?

    At the end of the period, Genfit s.a. (GNFT) held Total Cash and Cash Equivalents of 107.51M, accounting for 0.5 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.